{
  "docId": "019dd923-622c-750b-8b9b-8e8b0729eceb",
  "docSlug": "8a1ba1db7307",
  "documentTitle": "Pershing Square Portfolio (multi-position annual update)",
  "authorId": "01_Pershing_Square",
  "authorName": "Pershing Square Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2015-01-29 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 26,
  "pageCount": 81,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Uses red 'x' icons to emphasize hostile actions.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-8e8b0729eceb/26",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-8e8b0729eceb#slide-26",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Despite a large premium offer, the Allergan board’s response was hostile and anti-shareholder",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcdc-8e145f456bb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "list",
      "text": "Only after failing in California Federal Court litigation to bar Pershing Square from voting to remove directors did Allergan sign a confidentiality agreement with a second bidder, Actavis, to negotiate the sale of the company",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3aeaf3f8-aad9-4984-afeb-ab7322b1dc0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.04,
        "y": 0.51
      },
      "kind": "list",
      "text": "Allergan's response warranted a change in the board",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d369663-575f-4e76-8bc1-ec1083171b76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.1,
        "y": 0.26
      },
      "kind": "list",
      "text": "Threats to engage in preclusive transactions\nRefusal to engage with all bidders\nAttacks against Valeant's business\nObstruction of Special Meeting and shareholder rights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62448d79-6076-487d-9b17-28e0e3242b25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "list",
      "text": "Despite extraordinarily onerous special meeting bylaws, Pershing Square received support from shareholders holding ~36% (greater than 25% required) of Allergan shares to call a Special Meeting on December 18th, 2014",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6381385a-c3a4-4aae-ae4e-b854af4c78c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "list",
      "text": "Despite a large premium offer, the Allergan board's response was hostile and anti-shareholder",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1232ec0-b1ac-411e-b0af-dd3a23f39e01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Allergan's Response to the Unsolicited Offer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25933ebf-aa39-4233-b84e-54887434f390",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "d8c973b3-627f-4241-9021-0c198a91cb78",
      "evidence": "The slide highlights contradictory actions by the board to justify a change in leadership.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 81,
      "from": 21,
      "beatId": "ca908ed6-09de-4041-87d4-d25c486e2e39",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "Detailed portfolio company updates and performance data",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}